Search Saint Luke's

The use of prescription drugs for ADHD has significantly increased in the past few decades. James O'Keefe, MD studies the link between these medications and cardiovascular events.

The groundbreaking STEP-HFpEF study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named one of the top advances by the American Heart Association.

BBC News talked to Dr. Mikhail Kosiborod about new findings on the cardiovascular effects of semaglutide.

A growing body of evidence correlates shorter running sessions to significant health benefits, especially those regarding longevity and mental health.

A team of cardiologists has used cardiac imaging technology to confirm that cardiovascular disease was a significant issue thousands of years ago.

Dr. Timothy Bateman spoke with Cardiovascular Business about his group's findings and what it is like to work with flurpiridaz.

Percutaneous coronary intervention is associated with significant short-term improvements in high-risk patients with complex coronary artery disease who are ineligible for coronary artery bypass grafting, according to a new analysis.

Semaglutide improves symptoms in both men and women who present with heart failure. When it comes to weight loss, however, the drug appears to benefit women much more than men.

Cardiovascular Business spoke with Dr. Timothy Bateman about his views on SPECT advances and its longevity in the coming years.

TAVR in asymptomatic and minimally symptomatic patients is associated with a high survival rate, but relatively minor improvements, according to new research.